Ignite Creation Date:
2024-05-05 @ 10:32 PM
Last Modification Date:
2024-10-26 @ 10:19 AM
Study NCT ID:
NCT01121588
Status:
TERMINATED
Last Update Posted:
2023-11-09
First Post:
2010-05-10
Brief Title:
An Investigational Drug Crizotinib PF-02341066 Is Being Studied In Tumors Except Non-Small Cell Lung Cancer That Are Positive For Anaplastic Lymphoma Kinase ALK
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB PF-02341066 IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE ALK GENE LOCUS
Status:
TERMINATED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Termination of further treatment on the study due to the availability of commercial supply or a rollover study NCT05160922 that will allow active subjects to continue receiving treatment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PROFILE 1013 | None | None | None |
| 2010-022978-14 | EUDRACT_NUMBER | None | None |